Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01).
Authors
Takayuki Yoshino
National Cancer Center Hospital East, Kashiwa, Japan
Takayuki Yoshino , Maria Di Bartolomeo , Kanwal Pratap Singh Raghav , Toshiki Masuishi , Hisato Kawakami , Kensei Yamaguchi , Tomohiro Nishina , Zev A. Wainberg , Elena Elez , Javier Rodriguez , Marwan Fakih , Fortunato Ciardiello , Kapil Saxena , Kojiro Kobayashi , Emarjola Bako , Yasuyuki Okuda , Gerold Meinhardt , Axel Grothey , Salvatore Siena
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03384940
DOI
10.1200/JCO.2022.40.4_suppl.119
Abstract #
119
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01).
First Author: Kensei Yamaguchi
Poster
2020 ASCO Virtual Scientific Program
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized, phase II, multicenter, open-label study (DESTINY-Gastric01).
First Author: Kohei Shitara
Poster
2023 ASCO Annual Meeting
First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142.
First Author: Heinz-Josef Lenz
Poster
2022 ASCO Annual Meeting
Interim analysis of the phase II AVETUXIRI trial: Avelumab combined with cetuximab and irinotecan for treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
First Author: Nicolas Huyghe